Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Anal Cancer Therapeutics - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Risk Factors for Anal Cancer
2.5 Symptoms
2.6 Diagnosis
2.6.1 Physical Exam and History
2.6.2 Endoscopy
2.6.3 Biopsy
2.6.4 Ultrasound
2.6.5 Digital Rectal Examination (DRE)
2.6.6 CT (Computerized Tomography) Scan
2.6.7 Human Papillomavirus Test
2.6.8 Other Recent Methods to Detect HPV Infections
2.7 Staging of Anal Cancer
2.8 Treatment for Patients with Anal Cancer
2.8.1 Surgery
2.8.2 Radiation Therapy
2.8.3 Chemotherapy
2.8.4 Limitations of Current HPV Vaccines
2.9 Treatment by Stage of the Disease
2.10 GlobalData Pipeline Report Guidance
3 Anal Cancer Therapeutics - Market Characterization
3.1 Anal Cancer Therapeutics Market Size (2006-2011) - Global
3.2 Anal Cancer Therapeutics Market Forecast (2011-2019) - Global
3.3 Anal Cancer Therapeutics Market Size (2006-2011) - The US
3.4 Anal Cancer Therapeutics Market Forecast (2011-2019) - The US
3.5 Anal Cancer Therapeutics Market Size (2006-2011) - The UK
3.6 Anal Cancer Therapeutics Market Forecast (2011-2019) - The UK
3.7 Anal Cancer Therapeutics Market Size (2006-2011) - France
3.8 Anal Cancer Therapeutics Market Forecast (2011-2019) - France
3.9 Anal Cancer Therapeutics Market Size (2006-2011) - Germany
3.10 Anal Cancer Therapeutics Market Forecast (2011-2019) - Germany
3.11 Anal Cancer Therapeutics Market Size (2006-2011) - Italy
3.12 Anal Cancer Therapeutics Market Forecast (2011-2019) - Italy
3.13 Anal Cancer Therapeutics Market Size (2006-2011) - Spain
3.14 Anal Cancer Therapeutics Market Forecast (2011-2019) - Spain
3.15 Anal Cancer Therapeutics Market Size (2006-2011) - Japan
3.16 Anal Cancer Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Anal Cancer Therapeutics Market
3.17.1 Drivers for the Anal Cancer Therapeutics Market
3.17.2 Barriers for the Anal Cancer Therapeutics Market
3.18 Opportunity and Unmet Need
3.18.1 Opportunity and Unmet Need for the Anal Cancer Therapeutics Market
3.19 Key Takeaway
4 Anal Cancer Therapeutics Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.2.1 Competitor Assessment within Different Categories Employed in Anal Cancer Treatment
4.3 Product Profile for Recommended Regimens for Anal Cancer Therapeutics Market
4.3.1 5- Fluorouracil in Combination with Mitomycin
4.3.2 5- FU in Combination with Cisplatin
4.3.3 Prophylactic Vaccine Used for Anal Cancer: Gardasil
4.4 Key Takeaway
5 Anal Cancer Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Anal Cancer Therapeutics - Pipeline by Phases of Development
5.3.1 Anal Cancer Therapeutics - Phase II Pipeline
5.3.2 Anal Cancer Therapeutics - Phase I Pipeline
5.3.3 Anal Cancer Therapeutics - Preclinical Pipeline
5.4 Anal Cancer Therapeutics- Pipeline by Mechanism of Action
5.4.1 Technology Trends Analytic Framework
5.5 Molecule Profile for Drugs under Clinical Development
5.5.1 Panitumumab in Combination with mitomicin C, 5-FU and Radiation Therapy
5.5.2 TheraCIM (Nimotuzumab) in Combination with Radiation Therapy
5.6 Key Takeaway
6 Anal Cancer Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
7 Anal Cancer Therapeutics - Strategic Assessment
7.1 Anal Cancer Therapeutics - Implications for Future Market Competition
8 Anal Cancer Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 YM BioSciences Inc. (YM BioSciences)
8.2.2 PDS Biotechnology Corporation (PDS)
9 Anal Cancer Therapeutics - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography
List of Tables
Table 1: Anal Cancer Therapeutics - Incidence Rate
Table 2: Definitions of TNM
Table 3: TNM Classification and Stages of Anal Cancer
Table 4: Description of Prophylactic Anal Cancer Vaccine
Table 5: Anal Cancer Therapeutics Market, Seven Major Markets, Revenue ($m), 2006-2011
Table 6: Anal Cancer Therapeutics Market, Major Markets, Forecast ($m), 2011-2019
Table 7: Anal Cancer Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 8: Anal Cancer Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 9: Anal Cancer Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 10: Anal Cancer Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 11: Anal Cancer Therapeutics Market, France, Revenue ($m), 2006-2011
Table 12: Anal Cancer Therapeutics Market, France, Forecast ($m), 2011-2019
Table 13: Anal Cancer Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 14: Anal Cancer Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 15: Anal Cancer Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 16: Anal Cancer Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 17: Anal Cancer Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 18: Anal Cancer Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 19: Anal Cancer Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 20: Anal Cancer Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 21: Gardasil Approvals and Fillings
Table 22: Anal Cancer Therapeutics - Phase II Pipeline, 2011
Table 23: Anal Cancer Therapeutics - Phase I Pipeline, 2011
Table 24: Anal Cancer Therapeutics - Preclinical Pipeline, 2011
Table 25: Anal Cancer - Clinical Trials by Country, 2011
Table 26: Anal Cancer - Clinical Trials by Phase, 2011
Table 27: Anal Cancer - Clinical Trials by Status, 2011
Table 28: Anal Cancer - Overall Sponsors, 2011
Table 29: Anal Cancer - Prominent Sponsors, 2011
List of Figures
Figure 1: Human Papillomavirus Infection and Replication in Anogenital Epithelial Cells
Figure 2: Anal Cytology Screening for Anal Squamous Intraepithelial Lesions
Figure 3: Stages of Anal Cancer
Figure 4: Anal Cancer Surgery with Colostomy, 2011
Figure 5: Chemotherapy Regimens for Anal Cancer
Figure 6: Anal Cancer Treatment by Stage of the Disease, 2011
Figure 7: Anal Cancer Treatment Protocols - Chemo-radiation Therapy or Chemotherapy by Stage, 2011
Figure 8: Anal Cancer Therapeutics Market, Seven Major Markets, Revenue ($m), 2006-2011
Figure 9: Anal Cancer Therapeutics, Market Share ($m), 2011
Figure 10: Anal Cancer Therapeutics Market, Major Markets, Forecast ($m), 2011-2019
Figure 11: Anal Cancer, Seven Major Markets, Market Share ($m), 2019
Figure 12: Anal Cancer Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 13: Anal Cancer Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 14: Anal Cancer Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 15: Anal Cancer Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 16: Anal Cancer Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 17: Anal Cancer Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 18: Anal Cancer Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 19: Anal Cancer Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 20: Anal Cancer Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 21: Anal Cancer Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 22: Anal Cancer Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 23: Anal Cancer Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 24: Anal Cancer Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 25: Anal Cancer Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 26: Anal Cancer Therapeutics Market, Drivers and Barriers, 2011
Figure 27: Anal Cancer Therapeutics Market, Drivers and Barriers and Its Influence, 2011
Figure 28: Opportunity and Unmet Need for Anal Cancer Therapeutics Market, 2011
Figure 29: Anal Cancer Therapeutics Market - Strategic Competitor Assessment, 2011
Figure 30: Anal Cancer Therapeutics - Pipeline by Phase of Development, (%), 2011
Figure 31: Anal Cancer Therapeutics - Pipeline by Phase of Development, 2011
Figure 32: Anal Cancer Therapeutics- Clinical Pipeline by Mechanism Of Action, 2011
Figure 33: Anal Cancer Therapeutics- Technology Trends Analytics Framework, 2011
Figure 34: Anal Cancer - Clinical Trials by Country, 2011
Figure 35: Anal Cancer - Clinical Trials by Phase, 2011
Figure 36: Anal Cancer - Clinical Trials by Status, 2011
Figure 37: Anal Cancer - Overall Sponsors, 2011
Figure 38: Anal Cancer - Prominent Sponsors, 2011
Figure 39: Implications for Future Market Competition in Anal Cancer Therapeutics Market, 2011
Figure 40: Anal Cancer Therapeutics - Pipeline by Company, 2011
Figure 41: GlobalData Market Forecasting Model 64
